purpos
revieww
describ
histori
passiv
immun
provid
context
seri
articl
follow
histori
passiv
immun
antibodi
prevent
treat
infecti
diseas
stori
differ
era
extraordinari
era
discoveri
clinic
implement
chemic
natur
antibodi
even
known
empir
process
provid
resourc
reagent
use
describ
character
humor
immun
better
defin
chemic
properti
structur
antibodi
extend
clinic
use
immunoglobulin
product
treat
prevent
multipl
viral
bacteri
diseas
ensu
sever
decad
next
distinct
era
came
discoveri
process
produc
monoclon
antibodi
mab
develop
specif
therapi
interestingli
mab
technolog
result
mani
product
treat
autoimmun
allerg
diseas
one
common
infecti
diseas
respiratori
syncyti
viru
restrict
popul
highrisk
infant
recent
findingsth
current
era
began
seri
public
demonstr
process
rapidli
produc
human
mab
summarythi
technolog
combin
new
sequenc
technolog
advanc
structur
biolog
atomiclevel
molecular
design
increas
capac
synthet
biolog
promis
new
opportun
appli
passiv
immun
prevent
treatment
infecti
diseas
antibodi
critic
immun
infecti
diseas
appli
prevent
treatment
bacteri
viral
infect
centuri
nobel
prize
award
discoveri
relat
treatment
infecti
diseas
antibodi
describ
humor
immun
defin
chemic
structur
antibodi
product
monoclon
antibodi
mab
explain
mechan
antibodi
divers
highlight
histor
event
guid
understand
use
antibodi
prevent
treat
infecti
diseas
sinc
end
th
centuri
attempt
provid
context
investig
clinic
use
antibodi
shape
current
commerci
capac
regulatori
practic
scienc
biolog
gener
confluenc
technolog
advanc
includ
high
throughput
process
human
mab
isol
option
use
passiv
antibodi
infecti
diseas
improv
public
health
still
expand
emil
von
behr
award
first
nobel
prize
physiolog
medicin
discoveri
serum
therapi
diphtheria
shibasaburo
kitasato
show
serum
rabbit
immun
tetanu
toxin
could
prevent
tetanu
rabbit
phenomenon
rapidli
demonstr
diphtheria
toxin
led
term
antitoxin
probabl
motiv
use
term
translat
antibodi
paul
erlich
paper
erlich
work
demonstr
increas
dose
bacteri
toxin
could
provid
immun
lethal
dose
toxin
basi
serum
therapi
find
work
also
led
concept
activ
passiv
immun
nobel
prize
award
establish
field
humor
immun
fit
highlight
erlich
contribut
initi
concept
passiv
immun
year
anniversari
death
von
behr
erlich
work
togeth
standard
product
serum
treatment
diphtheria
standard
serum
product
dairi
cattl
hors
led
establish
new
compani
provid
new
direct
exist
pharmaceut
compani
exampl
erlich
becam
associ
hoechst
von
behr
establish
compani
eventu
becam
aventi
behr
part
sanofi
pasteur
interestingli
compani
organ
like
lederl
success
pharmaceut
compani
becam
part
wyeth
pfizer
began
new
york
butantan
stateown
oper
organ
still
produc
antivenom
antitoxin
vaccin
sao
paulo
brazil
origin
hors
farm
primarili
purpos
make
antiserum
bacteri
toxin
new
field
passiv
immun
result
varieti
event
influenc
landscap
modern
biolog
incid
involv
diphtheria
antitoxin
contamin
tetanu
toxin
led
biolog
control
act
gave
respons
regul
biolog
hygien
laboratori
public
health
marin
hospit
servic
figur
hygen
laboratori
becam
nation
institut
health
part
nation
institut
health
regul
immunoglobulin
product
resid
time
respons
transfer
food
drug
administr
fda
fda
center
drug
evalu
research
cder
respons
regul
immunoglobulin
monoclon
antibodi
anoth
interest
byproduct
industri
serum
therapi
immun
hors
make
bacteri
antitoxin
led
discoveri
adjuv
notic
serum
titer
higher
anim
infect
site
toxin
inject
led
frenchman
gaston
ramon
perform
initi
studi
adjuv
deriv
bacteri
cell
wall
immun
anim
sera
treatment
diseas
late
follow
era
serum
therapi
viral
bacteri
diseas
fact
influenza
pandem
serum
recov
patient
use
success
treat
acut
ill
patient
role
serum
therapi
expand
mani
infect
beyond
influenza
first
half
th
centuri
clinic
benefit
demonstr
viral
diseas
like
measl
polio
invas
bacteri
infect
includ
pneumococcu
haemophilu
influenza
b
meningococcu
clinic
program
turn
contribut
basic
knowledg
antibodi
known
specif
antitoxin
activ
associ
precipitin
agglutinin
underli
chemistri
antibodi
still
understood
address
work
michael
heidelberg
oswald
averi
common
practic
treat
pneumococc
pneumonia
typespecif
antiserum
deriv
hors
first
use
specif
antiserum
reagent
show
antigen
target
carbohydr
compris
capsul
pneumococcu
groundbreak
assum
antigen
protein
use
rel
purifi
antibodycontain
fraction
serum
new
knowledg
pneumococc
antigen
carbohydr
abl
prove
antibodi
protein
heidelberg
went
find
way
quantifi
precipitin
agglutinin
reaction
provid
basi
modern
serolog
assay
discoveri
antibiot
interest
treatment
bacteri
infect
serum
therapi
wane
howev
field
remain
activ
infect
treat
antibiot
greatli
advanc
dr
edwin
cohn
discoveri
purifi
antibodi
ethanol
fraction
plasma
mani
effect
polyclon
antibodi
product
develop
use
process
target
either
prevent
viral
infect
treatment
bacteri
toxin
relat
diseas
tabl
product
includ
diphtheria
immun
globulin
tetanu
immun
globulin
immun
serum
globulin
rabi
immun
globulin
hepat
b
immun
globulin
varicella
zoster
immun
globulin
cmv
globulin
botulinum
immun
globulin
technolog
ethanol
fraction
plasma
result
success
product
suppli
rel
small
market
howev
ultim
limit
first
largescal
infecti
diseas
applic
rsvigiv
respigam
polyclon
antibodi
product
prevent
respiratori
syncyti
viru
rsv
licens
use
highrisk
infant
pivot
trial
includ
prematur
infant
bronchopulmonari
dysplasia
respigam
shown
reduc
number
rsv
hospit
percent
time
hospit
infant
percent
two
year
later
product
demand
quickli
outstrip
plasma
avail
human
monoclon
antibodi
palivizumab
synagi
licens
beyond
suppli
advantag
monoclon
antibodi
technolog
offer
increas
consist
biolog
reduc
risk
infect
due
blood
born
pathogen
diminish
number
advers
event
administr
palivizumab
also
potent
polyclon
product
result
reduc
volum
administr
intramuscular
use
advantag
properti
monoclon
antibodi
technolog
would
soon
exploit
applic
field
medicin
last
three
decad
thirti
therapeut
monoclon
antibodi
licens
dramat
impact
cancer
ulcer
coliti
crohn
diseas
rheumatoid
arthriti
multipl
sclerosi
psoriasi
system
lupu
allergi
well
orphan
diseas
although
palivizumab
one
first
licens
monoclon
antibodi
two
therapeut
monoclon
antibodi
infecti
diseas
indic
success
altern
method
combat
infecti
diseas
cost
effect
vaccin
antivir
small
molecul
partial
explain
limit
number
product
although
resist
bacteria
antibiot
loom
major
public
health
threat
monoclon
antibodi
limit
success
stori
treat
bacteri
diseas
thu
current
activ
area
monoclon
develop
focus
viral
diseas
without
avail
vaccin
eg
hiv
ebola
sar
mer
viral
diseas
limit
effect
antivir
drug
eg
influenza
rabi
bacteri
toxinmedi
diseas
eg
anthrax
c
difficil
coliti
monoclon
antibodi
product
current
licens
progress
toward
late
stage
develop
infecti
diseas
list
tabl
includ
program
inact
yet
advanc
phase
studi
potenti
antibodi
prevent
treat
hiv
discuss
accompani
articl
comment
area
activ
develop
antibodi
typic
consid
design
prevent
infect
diseas
produc
toxin
target
organ
distant
site
infect
long
incub
period
prolong
replic
postexposur
treatment
antibodi
highli
effect
exampl
hepat
immun
globulin
protect
hepat
b
even
given
exposur
rabi
anoth
exampl
postexposur
treatment
immunoglobulin
effect
also
illustr
import
use
monoclon
antibodi
technolog
replac
polyclon
product
expens
limit
suppli
often
less
potent
still
death
due
rabi
worldwid
half
victim
children
although
vaccin
administr
combin
human
rabi
immun
globulin
hrig
effect
prevent
rabi
follow
exposur
expens
polyclon
antibodi
limit
use
two
product
develop
could
remedi
situat
consist
two
monoclon
antibodi
combin
phase
trial
siirmab
consist
singl
human
monoclon
antibodi
complet
enrol
pivot
trial
india
project
monoclon
antibodi
product
could
wide
avail
lowincom
countri
due
lower
cost
good
process
develop
activ
local
manufactur
bacteri
toxin
also
offer
attract
target
monoclon
antibodi
develop
suggest
earliest
effect
polyclon
antibodi
product
neutral
toxin
diphtheria
tetanu
immun
globulin
recent
exampl
licensur
monoclon
antibodi
direct
anthrax
toxin
raxibacumab
licens
treatment
inhal
anthrax
note
first
biolog
licens
fda
accord
anim
rule
contrast
establish
efficaci
clinic
field
trial
stabil
monoclon
antibodi
longterm
storag
immediaci
neutral
make
product
uniqu
suitabl
indic
c
difficil
coliti
anoth
exampl
bacteri
toxin
mediat
diseas
activ
monoclon
product
late
stage
develop
consist
two
antibodi
one
direct
toxin
one
direct
toxin
b
product
phase
studi
evalu
efficaci
prevent
recurr
diseas
interest
consid
passiv
administ
monoclon
antibodi
therapeut
trial
implic
vaccin
develop
efficaci
passiv
administ
antibodi
would
valid
antigen
select
guid
atom
level
design
candid
vaccin
furthermor
trial
could
establish
specif
biomark
protect
vaccin
studi
util
efficaci
monoclon
antibodi
approach
therapeut
monoclon
antibodi
trial
identifi
vaccin
target
appeal
infecti
diseas
perhap
notabl
hiv
exampl
immun
serum
use
treat
viral
diseas
symptomat
phase
ill
even
viremia
may
peak
note
convalesc
serum
use
treat
peopl
influenza
epidem
sar
epidem
explor
patient
ebola
infect
report
anecdot
anoth
exampl
treatment
argentin
hemorrhag
fever
caus
arenaviru
junin
viru
patient
shown
benefit
immun
serum
administ
within
one
week
symptom
began
basi
therapeut
effect
shown
associ
neutral
activ
nt
correl
well
method
antibodi
quantif
complement
fixat
immunofluoresc
nt
antibodi
abl
effect
control
viremia
nt
unit
need
per
kg
patient
bodi
weight
establish
treatment
protocol
interestingli
late
neurolog
syndrom
patient
treat
immun
serum
occur
untreat
survivor
syndrom
begin
sever
week
appar
resolut
acut
infect
includ
fever
symptom
cerebellar
cranial
nerv
damag
pathogenesi
well
understood
presum
involv
either
fail
clear
viru
cn
facilit
transport
viru
cn
note
content
issu
midst
anoth
historymak
era
field
passiv
immun
larg
part
due
develop
technolog
rapidli
isol
human
monoclon
antibodi
public
milstein
describ
method
produc
murin
monoclon
antibodi
mab
immort
b
cell
hybridoma
landmark
paper
led
nobel
prize
varieti
approach
produc
human
monoclon
antibodi
evolv
transform
technolog
report
heavi
light
chain
immunoglobulin
ig
gene
amplifi
singl
human
b
cell
clone
express
vector
high
throughput
version
approach
report
advanc
along
innov
cell
sort
clone
allow
discoveri
new
human
mab
occur
larg
scale
particularli
valuabl
studi
infecti
diseas
new
intervent
need
describ
issu
avail
multipl
human
antibodi
open
new
avenu
understand
diseas
pathogenesi
vaccineinduc
immun
consid
context
new
sequenc
technolog
structureguid
atom
level
design
new
harvest
human
mab
provid
new
product
therapeut
potenti
made
new
investig
possibl
includ
defin
antigen
topographi
glycoprotein
ectodomain
site
neutral
sensit
isol
antibodi
particular
function
properti
use
sequenc
character
ontogeni
antibodi
respons
encount
immunogen
molecular
engin
antibodi
improv
potenc
specif
halflif
understand
role
posttransl
modif
antibodi
advent
synthet
antibodi
higher
potenc
longer
halfliv
made
mammalian
cell
yeast
plant
transgen
anim
foster
hope
promis
passiv
immun
option
avail
grow
number
infecti
diseas
new
manufactur
deliveri
approach
also
make
develop
rapid
costeffect
passiv
immun
approach
readili
appli
emerg
infecti
diseas
threat
avail
low
resourc
set
improv
public
health
passiv
administr
antibodi
prevent
treat
infecti
diseas
done
success
year
advent
regul
biolog
manufactur
use
immunoglobulin
antibodi
product
outstand
record
safeti
efficaci
recent
revolut
technolog
isol
character
human
monoclon
antibodi
promis
new
era
progress
option
manag
infecti
diseas
threat
public
health
graham
